Emerging Hsp90 Inhibitors: From Discovery to Clinic

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Emerging Hsp90 Inhibitors: From Discovery to Clinic

Anti-Cancer Agents in Medicinal Chemistry, 6(1): 1-8.

Author(s): G. Chiosis, A. Rodina and K Moulick.

Affiliation: Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 482, New York, NY10021, USA;


Hsp90 is a chaperone with important roles in maintaining transformation and in elevating the survival and growth potential of cancer cells. Activation of signaling pathways mediated by Hsp90 protein clients is necessary for cell proliferation, regulation of cell cycle progression and apoptosis. Additionally, gain-of-function mutations responsible for transformation often require Hsp90 for the maintenance of their folded, functionally active conformations. These characteristics promise Hsp90 as an important target in cancer therapy and prompt for the identification, development and clinical translation of small molecule inhibitors of the chaperone. This review intends to update the reader on the status of several existing and emerging classes of direct inhibitors of Hsp90 ATPase activity.


17AAG, 17DMAG, PU-class Hsp90 inhibitors, radicicol and derivatives, 3,4-diarylpyrazoles, anti-cancer therapeutics.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 1
First Page: 1
Last Page: 8
Page Count: 8
DOI: 10.2174/187152006774755483

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science